13D Filing: Glaxosmithkline Plc and Innoviva Inc. (NASDAQ:INVA)

Item 1. Security and Issuer.

This Amendment No. 6 to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on December 9, 2010 (as amended by Amendment No. 1 filed on April 2, 2012, Amendment No. 2 filed on May 16, 2012, Amendment No. 3 filed on August 1, 2013, Amendment No. 4 filed on November 4, 2014, and Amendment No. 5 filed on August 25, 2016, the “Schedule 13D” and as amended by this Amendment No. 6, the “Statement”) with respect to the shares of common stock, par value $0.01 per share (the “Common Stock”) of Innoviva, Inc., a Delaware corporation (the “Issuer” or “Innoviva”). GlaxoSmithKline plc (“GSK”) is filing this amendment to reflect its current intent to vote for the Issuer board of directors’ nominees at the 2017 annual meeting of stockholders of the Issuer scheduled to be held on April 20, 2017 (the “2017 Annual Meeting”). The Issuer’s principal executive offices are located at 2000 Sierra Point Parkway, Suite 500, Brisbane, CA 94005. Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D.

Item 2. Identity and Background.

The response set forth in Item 2 of the Schedule 13D is hereby amended by deleting in its entirety Schedule 1 as attached to Amendment No. 5, and replacing it with Schedule 1 attached hereto.

Item 4. Purpose of Transaction.

The response set forth in Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following:

GSK Intends to Vote for Innoviva’s Board at Innoviva’s 2017 Annual Meeting

GSK today issued the following statement with regard to Innoviva’s upcoming 2017 Annual Meeting:

“GSK has been a long-time partner of Innoviva and we continue to value the collaborative and productive relationship.  GSK owns approximately 29.3% of the outstanding shares of Common Stock.

As a shareholder, we have reviewed the nominees, proposals and public communications from both Innoviva and Sarissa Capital Management LP.

We support Innoviva’s Board and management team’s continuing effort to deliver significant shareholder value. We also believe that engagement with shareholders is important, and recognise Innoviva’s engagement and serious consideration of the feedback it has received from shareholders, which has been a significant element in determining our voting decision. Specifically, we have noted Innoviva’s recent announcement that it will review its cost and executive compensation structures, with an expectation of achieving meaningful savings in core operating costs while maintaining its strong revenue growth. We have also noted the Innoviva Board’s continuing commitment to delivering strong and increasing returns for shareholders over the long-term.

GSK intends to vote for Innoviva’s Board of Director nominees at the 2017 Annual Meeting.”

GSK reserves the right (i) to formulate other plans and proposals; (ii) to take any other actions with respect to its investment in the Issuer, including any or all of the actions set forth in subsections (a) through (j) of Item 4 of Schedule 13D; and (iii) to acquire additional shares of Common Stock or to dispose of some or all of the Common Stock beneficially owned by it in the open market, through privately negotiated transactions or otherwise. GSK may at any time reconsider and change its plans or proposals relating to the foregoing.

Item 5. Interest in Securities of the Issuer.

The response set forth in Item 5 of the Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: April 13, 2017

                                                                                                                   GLAXOSMITHKLINE PLC

Name		Business Address		Principal Occupation or Employment		Citizenship
Board of Directors
Emma Walmsley		980 Great West Road Brentford Middlesex, England TW8 9GS		Executive Director and Chief Executive Officer		British
Professor Sir Roy Anderson		980 Great West Road Brentford Middlesex, England TW8 9GS		Independent Non-Executive Director & Scientific Expert		British
Manvinder Singh Banga		980 Great West Road Brentford Middlesex, England TW8 9GS		Senior Independent Non-Executive Director		Indian
Dr. Patrick Vallance		980 Great West Road Brentford Middlesex, England TW8 9GS		Executive Director and President, R&D		British
Simon Dingemans		980 Great West Road Brentford Middlesex, England TW8 9GS		Executive Director and Chief Financial Officer		British
Lynn Elsenhans		980 Great West Road Brentford Middlesex, England TW8 9GS		Independent Non-Executive Director		US
Dr. Jesse Goodman		980 Great West Road Brentford Middlesex, England TW8 9GS		Independent Non-Executive Director & Scientific Expert		US
Sir Philip Hampton		980 Great West Road Brentford Middlesex, England TW8 9GS		Non-Executive Chairman		British
Judy Lewent		980 Great West Road Brentford Middlesex, England TW8 9GS		Independent Non-Executive Director		US
Urs Rohner		980 Great West Road Brentford Middlesex, England TW8 9GS		Independent Non-Executive Director		Swiss
Dr. Vivienne Cox		980 Great West Road Brentford Middlesex, England TW8 9GS		Independent Non-Executive Director		British